Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The biotech’s stock more than doubled following reported Phase 3 success versus the existing standard of care, a move that also appears to have crushed losses for investors betting against the company.
THE APEX TIMES
THE APEX TIMES
The biotech said an experimental mRNA-based cancer therapy cleared a key early step in a study that it expects could be the first of its kind if regulators approve it. Moderna and partner Merck were both referenced in the update.
THE APEX TIMES
Moderna and Merck & Co said their personalized mRNA cancer vaccine, intismeran, when combined with Keytruda, slowed melanoma recurrence and spread in a late-stage trial, sending Moderna shares higher.
THE APEX TIMES
U.S. stocks climbed Wednesday as investors weighed government debt buybacks ahead of Federal Reserve minutes. Shares of Moderna moved higher on reports tied to cancer drug developments, while bitcoin also extended gains.
THE APEX TIMES
A trial update involving Moderna and Merck for a melanoma vaccine helped lift Moderna’s stock, with the announcement described as a “landmark moment” in treatment for one of the deadliest forms of skin cancer.
THE APEX TIMES
Moderna’s stock jumped after a late-stage study of a cancer vaccine, developed with Merck, reported successful results in patients with melanoma, a development investors treated as a meaningful step forward for the drug program.
THE APEX TIMES
The jump follows market coverage claiming Moderna’s mRNA cancer vaccine, in collaboration with Merck, posted the first-ever positive Phase 3 outcome for the program.
THE APEX TIMES
Shares of Moderna climbed sharply and Merck also gained after investors reacted to late-stage trial results tied to a cancer vaccine in melanoma patients, according to a market report published Wednesday.
THE APEX TIMES
A Yahoo Finance segment highlighted a sharp market move in Moderna and Merck tied to results described as successful for a cancer vaccine trial aimed at melanoma. Neither company’s results were detailed in the broadcast note, leaving investors to wait for additional primary disclosures.
